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Abstract
Background The aim of this study was to assess outcomes
of laparoscopic sleeve gastrectomy (LSG) as a stand-alone
bariatric operation according to the Bariatric Analysis and
Reporting Outcome System (BAROS).
Methods Out of 112 patients included and operated on
initially, 84 patients (F/M, 63:21) were followed up for 14–
56 months (mean 22±6.75). Patients lost to follow-up did
not attend scheduled follow-up visits or they have with-
drawn their consent. Mean age was 39 years (range 17–67;
SD±12.09) with mean initial BMI 44.62 kg/m
2 (range
29.39–82.8; SD±8.17). Statistical significance was estab-
lished at the p<0.05 level.
Results Mean operative time was 61 min (30–140 min)
with mean hospital stay of 1.37 days (0–4; SD±0.77).
Excellent global BAROS outcome was achieved in 13% of
patients, very good in 30%, good in 34.5%, fair 9.5% and
failure in 13% patients 12 months after surgery. Females
achieved significantly better outcomes than males with the
mean 46.5% of excess weight loss (EWL) versus 35.3% of
EWL at 12 months (p=0.02). The mean percentage of
excess weight loss (%EWL) was 43.6% at 12 months and
46.6% at 24 months. Major surgical complication rate was
7.1%; minor surgical complication rate 8.3%. There was
one conversion (1.2%) due to the massive bleeding.
Comorbidities improved or resolved in numerous patients:
arterial hypertension in 62%, diabetes mellitus in 68.3%,
respectively.
Conclusions Presented LSG series shows that the LSG as a
stand-alone procedure provides acceptable %EWL and
good global BAROS outcomes. It significantly improves
comorbidities as well.
Keywords Laparoscopic sleeve gastrectomy.LSG.
Treatment outcomes.Bariatric analysis and reporting
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Introduction
Sleeve gastrectomy is one of the restrictive operations used
to treat morbid obesity [1]. This operation was first
described by Hess in 1988 as a part of the biliopancreatic
diversion with duodenal switch (BPD-DS) [2]. In 1999,
Gagner performed first laparoscopic sleeve gastrectomy
(LSG) also as a part of the BPD-DS [3]. Later, he used LSG
as a staged procedure for super morbid obesity to finally
use it as a stand-alone procedure. Since its first implemen-
tation in 2004 as a stand-alone bariatric operation, LSG was
proved to be sufficient and became one of the procedures
on the incline.
To assess the results of bariatric treatment, authors use
multiple outcome factors such as percentage of excess
weight loss, quality of life and complications including
postoperative deaths. Some use standardized tools such
as SF-36 scale [4], Sickness Impact Profile [5], Quality of
Well-Being Scale [6], and finally Bariatric Analysis and
Reporting Outcome System (BAROS) [7]. BAROS,
developed by Oria and Moorehead, is still the most
comprehensive questionnaire; it is also easy to use in
daily practice.
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(%EWL), improvement and/or resolution of comorbid
conditions, five aspects of quality of life (self-esteem,
physical activity, social activity, work, and sexual activity),
complications, and reoperations. The final outcome is based
on improvement, worsening, or no change in all five listed
domains giving the most comprehensive assessment of the
treatment results influencing not only the weight changes
but also its impact on patients’ general health and well
being.
The aim of this study was to assess outcomes of
laparoscopic sleeve gastrectomy used as a stand-alone
procedure for morbid obesity in a single institution in
Poland according to BAROS criteria.
Method
The study was designed as a single-institution, observa-
tional study. There was a retrospective data analysis
based on the patients’ hospital records (baseline data
including height, weight, comorbidities, data on opera-
tion, and complications) and prompted self-reported data
collected over the telephone (changes in time in weight,
complications, reoperations, changes in QoL, changes in
comorbidities, eating behaviors, and physical activity
changes). The patients were included since the introduc-
tion of the procedure in the authors’ institution. Between
13th March 2008 and 16th December 2009, 112 patients
signed informed consent and were initially qualified to
participate in the study and underwent LSG operation.
All operations were performed by one team of three
surgeons following one standard technique. Only the size
of bougie was under the surgeons’ discretion and was
slightly modified depending on the surgeon’s preference.
Twenty-five percent of patients were lost to follow-up.
These patients did not attend scheduled follow-up visits,
nor was there current contact data available or they have
withdrawn their consent to participate in the study on the
later stage when the data was collected in 6-month
intervals. The mortality data was checked against the
national registry. The remaining 84 patients (F/M, 63:21)
were followed-up for 14–56 months (mean 22±6.75).
Mean age was 39 years (range 17–67; SD±12.09;
38.7 years for females and 40.1 years for males
(p=0.6), with mean initial BMI 44.62 kg/m
2 (range
29.39–82.8; SD±8.17). Mean BMI significantly differed
between genders and was 43 kg/m
2 in females (SD±7.08)
a n d4 9 . 5k g / m
2 in males (SD±7.35; p=0.001). Statistical
analysis included only patients remaining in the follow-up
group to enable outcomes comparison. BAROS question-
naire was used for data collection along with the depart-
ment’s bariatric qualification chart 12 months after surgery
to assess preliminary outcomes of laparoscopic sleeve
gastrectomy. BAROS incorporates five strategic outcomes
of bariatric surgery: %EWL), resolution or improvement in
comorbid conditions, quality of life (the Moorehead–Ardelt
Quality of Life Questionnaire, QoL), surgical and medical
complications, as well as reoperations all scored as listed below
[7].Percentage EWL is stratified in five categories. The weight
gain is scored −1 point, 0–24% EWL gives 0 points, 25–49%
EWL +1 point, 50–74% EWL +2 points, >75% +3 points.
Comorbidities resolution gives +2 points, its improvement
gives +1 point, no change is scored 0 and worsening gives −1
point. Quality of life assessment based on Moorehead–Ardelt
QoL Questionnaire evaluates five aspects of live: self-esteem,
physical activity, social involvement, ability to work, and
interest in sex. Each aspect is evaluated as: much worse,
worse, no change, improved, significantly improved receiving
−0.5, −0.25, 0, +0.25, or +0.5 points, respectively. Each major
complication deducts one point and a minor complication
deducts 0.2 points. Finally, any reoperation deducts one point
from the score. Complications were stratified as minor and
major according to Oria et al. [7].
Statistical analysis was performed using computer
software ‘Statistica’ 8.0, StatSoft, Krakow, Poland. Statis-
tical significance was established at the p<0.05 level for
Student’s t test and chi-square test.
Results
Background
Mean operative time was 61 min (range 30–140 min)
with mean hospital stay of 1.37 days (range 0–4; SD±
0.8). Nine out of 84 patients (10.7%) were subjected to
previous bariatric surgery. Two patients underwent
vertical gastric banding, six patients had laparoscopic
adjustable gastric banding procedure, and one patient had
laparoscopic sleeve gastrectomy. The linear regression
model did not show any statistically significant positive
or negative impact of having previous bariatric surgery
on outcomes of LSG in presented series. Super morbid
obesity with BMI>50 kg/m
2 was present in 21.4%
(N=18) of patients before the operation and was reduced
to 3.6% (N=3) after the operation. Of the patients, 66.7%
declared having been obese since childhood and 65.5%
having at least one first-degree relative suffering from
obesity. Of the patients, 81% declared having changed
their diet with significant calories and carbohydrates
intake reduction following the surgery. Thirty-three per-
cent declared increase of physical activity (more than three
times a week) and 56% of patients did not commence any
physical activity postoperatively according to self-
reported data.
1844 OBES SURG (2011) 21:1843–1848BAROS Data
Initial mean BMI of 44.6 kg/m
2 has reduced every 6 months
to 36.8, 35.2, 35.9, 35.3, and 32.2 kg/m
2 consecutively at 6,
12, 18, 24, and 30 months after surgery (Table 1).
This corresponded with the mean 36.8% EWL in the
first 6 months and 43.6% EWL at 12 months, 45.4% EWL
at 18 months, 46.6% EWL at 24 months, and 51.1% of
EWL at 30 months following surgery. Figure 1 shows
changes of the percentage of excess weight loss in time.
Of the patients, 23.75%, 33%, 36.4%, 38.5%, and 50%
lost more than 50% of EWL at 6, 12, 18, 24, and 30 months
after surgery, respectively.
Eight most common comorbidities were assessed and
they were present in 59.5% (N=50) of patients before
surgery. Complete resolution of one comorbid condition
was observed in 23 cases and improvement or significant
improvement was observed in 21 cases. As the most
common, arterial hypertension improved or resolved in
62% of cases, and diabetes mellitus improved or resolved in
68.3% of affected patients. Changes in all present comorbid
conditions have been presented in Table 2.
Results of the Moorehead–Ardelt Quality of Life
Questionnaire are shown in Table 3. The self-esteem and
physical activity aspects of QoL have improved most
significantly with interest in sex remaining in more than
50% of patients at the same level.
All surgical and medical complications were stratified as
major and minor as well as early and late according to the
Oria and Moorehead classification and were summarized in
Table 4.
There was one conversion (1.2%) to the open technique
due to the massive bleeding that could have not been
stopped with the laparoscopic approach and there were no
reoperations in the first 30 postoperative days. During the
follow-up period, three patients underwent another bariatric
operation due to unsatisfactory weight loss (1× resleeve, 2×
Roux-en-Y gastric bypass).
Based on all the above factors, the global BAROS
outcomes were calculated. Excellent outcome was achieved
BMI (kg/m
2)
Mean Minimum Maximum SD N
Preoperative 44.6 29.4 82.8 8.17 84
6 Months after surgery 36.8 23.1 75.3 7.69 80
12 Months after surgery 35.2 22.7 82.8 8.17 82
18 Months after surgery 36.0 23.7 90.3 10.64 55
24 Months after surgery 35.3 23.7 53.1 7.62 26
30 Months after surgery 32.2 25.6 40.3 5.04 10
Table 1 Body mass index
before and after surgery
% Excess Weight Loss following LSG
 Mean
 Mean±SD 
 Mean±1.96*SD 
61 2 1 8 2 4 3 0
Months
0
25
50
75
100
%
Fig. 1 Changes of percentage
of excess weight loss in time
following LSG
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(34.5%), fair in eight (9.5%), and failure in 11 (13%)
patients.
Further analysis has shown that females achieved
significantly better outcomes than males (Table 5) with
the mean 46.5% of EWL versus 35.3% of EWL at
12 months (p=0.02). There was no statistically significant
difference in outcomes in correlation to education (p=0.17),
smoking (p=0.06), obesity of the first-degree relative
(p=0.13), childhood obesity (0.47), having had previous
bariatric surgery (p=0.59), declared increased physical
activity (p=0.96), and declared decreased calories intake
and diet modification (p=0.6).
The outline of the BAROS system excludes patients lost
to follow-up or the ones who died during the operation or
shortly postoperatively. Among 112 patients initially
eligible for inclusion to the study, one female patient
(0.9%) died due to the pulmonary artery embolism on the
fifth postoperative day therefore was excluded from final
analysis.
Discussion
Among many well-established bariatric operations, LSG as
a stand-alone operation is relatively new. Nevertheless, the
operative technique is well-developed, established, and
standardized [1]. In the available literature, there are few
large series studies assessing its outcomes, and authors use
multiple outcome measures and assessment instruments;
therefore, the outcomes are difficult to compare [8–10].
BAROS give broader assessment of the outcome than the
use of percentage of the excess weight loss on its own [7].
Among limitations of BAROS is exclusion of patients with
perioperative deaths and the ones lost to follow-up.
In the presented series operative time of 61 min and
hospital stay of 1.37 days were shorter than in the recent
review by Shi et al. summarizing outcomes of 940 cases
(100.4 min and 4.4 days, respectively) [8].
Of the patients, 74% (81% offemales and 66.6% of males)
have achieved scores from good to excellent using BAROS
criteria. Of the operations, 13.1% in total were classified as
failures due to the poor global BAROS scores. Those patients
had poor weight loss or weight regain during the first
12 months following surgery with poor QoL scores and some
postoperative complications. Three (3.6%) of those patients
consecutively underwent another bariatric operations.
In opposition to the single criterion outcome measures,
BAROS shows global outcome apart from %EWL
including also QoL, resolution of comorbidities, compli-
cations, and need for reoperations [7]. Therefore, the
global impact of bariatric surgery is assumed greater than
only percentage of excess weight loss. In the presented series,
the mean percentage of the EWL of 43.6% at 12 months and
46.6% at 24 months of follow-up is lower than the expected
mean 60% and 65% loss of EWL in 12 and 24 months in
review by Shi et al. [8]. It is still much better than the results
published by Regan et al. [11] and Milone et al. [12]w i t h
EWL reaching only 33–35%. Nevertheless, the explanation
of this fact could potentially lie in the poor adherence to the
recommendations following surgery with only 32.9% of
patients declaring increase of physical activity to at least
Co-morbidity Before surgery Improvement Resolution No change Worsening
NN (%) N (%) N (%) N (%)
Arterial hypertension 42 12 (28.6) 14 (33.3) 16 (38) 0
Diabetes mellitus 22 6 (27.3) 9 (41) 7 (31.8) 0
Osteoarthritis 9 1 (11.1) 0 8 (89.9) 0
Asthma 4 1 (25) 0 3 (75) 0
Ischemic heart disease 3 0 0 3 (100) 0
Sleep apnoea 1 1 (100) 0 0 0
Thyroid disorders 6 0 0 6 (100) 0
Depression 1 0 0 1 (100) 0
Table 2 Improvement and
resolution of comorbidities
(N – responds to the
number of affected
patients – one patient
could have more than
one comorbidity)
Much worse (%) Worse (%) Same (%) Better (%) Much better (%)
Self-esteem 1 (1.2) 3 (3.6) 4 (4.8) 20 (23.8) 56 (66.6)
Physical activity 0 3 (3.6) 9 (10.7) 23 (27.4) 49 (58.3)
Social involvement 0 5 (5.9) 17 (20.2) 26 (31) 36 (42.9)
Ability to work 0 2 (2.4) 25 (29.7) 33 (39.3) 24 (28.6)
Interest in sex 3 (3.6) 3 (3.6) 44 (52.4) 16 (19) 18 (21.4)
Table 3 Moorehead–Ardelt
quality of life questionnaire
results
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not having any physical activity postoperatively. According
to the systematic review by Livhits et al., increase in physical
activity to at least 30 min a day, three times a week might be
associated with decrease of BMI by as much as 4% of initial
BMI [13]. Interestingly, as many as 79.7% of patients
declared change of their diet with significant calories and
carbohydrates intake reduction following surgery, which did
not correspond to %EWL and the global outcomes (p=0.6).
In the presented series, the LSG had greater influence on the
body mass reduction in females with statistically significant
higher percentage of excess weight loss at 12 months after
surgery (46.5% EWL versus 35.3% EWL (p=0.02)) and
thanks to that fact they achieved better outcomes than males.
Most probably, this difference is based mainly on signifi-
cantly lower initial BMI. Nevertheless, the data collected
during the study did not allow the analysis that would show
its background. If the above conclusion is true, one might
attempt a further conclusion that the LSG as a stand-alone
procedure is more effective in ‘slimmer’ patients with lower
initial BMI but to prove it further large case controlled studies
should be performed. The number of super morbid obesity
patients was reduced from 21.4% (N=18) to 3.6% (N=3),
although the weight loss was more limited in this group than
in the group of patients with lower preoperative BMI.
The well-known positive outcome of metabolic surgery is
resolution or improvement of comorbid medical conditions
[14]. Eight most common comorbidities were assessed and
they were present in 59.5% (N=50) of patients preopera-
tively. Complete resolution of one comorbid condition was
observed in 23 cases and improvement or significant
improvement was observed in 21 cases. Improvement or
resolution in 62% of cases of arterial hypertension and
68.3% of diabetes mellitus cases is just the same as achieved
by Basso et al. in their large series of 300 cases of LSG [9].
The quality-of-life assessment incorporated in BAROS
scale assumes changes of QoL in time following bariatric
surgery and compares current state with baseline from
before the surgery. Major positive changes in QoL were
reported in self-esteem and physical activity domains with
some improvement in social involvement and ability to
work and the moderate improvement in the interest in sex.
Major early surgical complications (listed by the BAROS
questionnaire)inthepresentedseriesreached4.8%,whichisa
Table 4 Complications
Surgical complications
Major 7.1% (N=6) Minor 8.3% (N=7)
Early 4.8% (N=4) Late 2.4% (N=2) Early 1.2% (N=1) Late 7.1% (N=6)
￿ Infarction of the upper splenic
pole 2.4% (N=2)
￿ Incisional hernia 2.4% (N=2) ￿ Small wound infection
1.2% (N=1)
￿ Persistent nausea or vomiting
4.8% (N=4)
￿ GI leak with peritonitis 1.2% (N=1) ￿ Stenosis of the stomach 1.2% (N=1)
￿ Wound abscess 1.2% (N=1) ￿ Electrolyte imbalance 1.2% (N=1)
Medical complications
Major 3.6% (N=3) Minor 15.5% (N=13)
Early 3.6% (N=3) Late 0% Early 4.8% (N=4) Late 10.7% (N=9)
￿ Depression 2.4% (N=2) ￿ Atelectasis 1.2% (N=1) ￿ Hair loss 4.8% (N=4)
￿ Breathing disturbances 1.2% (N=1) ￿ Vomiting 1.2% (N=1) ￿ Anemia 4.8% (N=4)
￿ Electrolyte imbalance
1.2% (N=1)
￿ Metabolic deficiency
(protein, vitamins) 1.2% (N=1)
￿ Urinary tract infection
1.2% (N=1)
Table 5 Outcome based on gender
Gender
Outcome Female Male
N=63 (100%) N=21 (100%)
Excellent 11 (17.5) 0
Very good 21 (33.3) 4 (19)
Good 19 (30.2) 10 (47.6)
Fair 5 (7.9) 3 (14.3)
Failure 7 (11.1) 4 (19.1)
OBES SURG (2011) 21:1843–1848 1847good result when compared to 12.1% in the review by Shi et
al. [8] and 9% in the single institution study by Basso et al.
[9]. On the contrary, upper splenic pole infarction was the
most frequent complication (two patients), followed by one
staples line leak and one wound abscess.
Interestingly, 10.7% of patients developed late medical
complications uncommon for restrictive bariatric proce-
dures but typical for malabsorptive procedures with anemia,
hair loss, and metabolic deficiencies including proteins and
vitamins deficiencies [15]. The study design did not allow
identification of the causative factors.
Out of the 112 patients initially qualified into the study
and operated on, one female patient (0.9%) died due to the
pulmonary artery embolism on the fifth postoperative day
despite antithrombotic prophylaxis. This patient was not
included in the outcomes analysis, as those patients are
excluded accordingly to the BAROS scale design. Mortality
was slightly higher than the mortality in other LSG studies
0.5% [16] and 0.3% [8]; nevertheless, surgery-related
mortality decreases with the center’s bariatric experience.
Conclusions
The presented series of laparoscopic sleeve gastrectomies
shows that it provides acceptable percentage of weight loss
and good global BAROS outcomes. It significantly
improves comorbidities. However, its metabolic impact still
needs further studies to explain deficiencies typical for
malabsorptive procedures.
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